Aggressive Intervention: Standard of Care and the ICU

When Catastrophic Antiphospholipid Syndrome (CAPS) is suspected, doctors do not wait for every test result to come back before starting treatment. Because the disease is a “thrombotic storm” that can damage multiple organs in days, the medical team uses a fast, aggressive approach called triple therapy. Based largely on expert consensus and observational registries, this combination attacks the problem from three different angles at the same time ^[1][2].

The Three Pillars of “Triple Therapy”

The goal of initial treatment is to stop new clots from forming, calm the overactive immune system, and remove the “bad” antibodies from the blood.

1. Anticoagulation (Blood Thinners): Intravenous (IV) unfractionated heparin is often favored in an unstable ICU patient because it works immediately and can be turned off quickly if a patient needs surgery or starts to bleed ^[1]. However, active bleeding, severe kidney impairment, or suspected HIT can change this plan.
2. High-Dose Glucocorticoids (Steroids): Patients typically receive “pulse” doses of powerful IV steroids (like methylprednisolone) for several days. These help dampen the massive inflammatory response that characterizes a CAPS episode ^[2][3].
3. Plasma Exchange or IVIG:
   • Plasma Exchange (Plasmapheresis): This procedure exchanges the patient’s plasma with donor fluid, which may help remove antiphospholipid antibodies, complement, and clotting proteins ^[4]. It carries risks such as bleeding, line infection, and low calcium.
   • IVIG (Intravenous Immunoglobulin): This is an immunomodulatory infusion of antibodies from donors that is an alternative or adjunct in selected cases ^[2]. Risks can include fluid shifts and kidney issues.

Identifying the Trigger

Treating the CAPS itself is only half the battle. In about 65% of cases, an underlying event “triggered” the storm ^[5]. The medical team must find and treat this trigger simultaneously to stop the cycle:

• Infections: Doctors will start broad antibiotics or antivirals if an infection is suspected ^[6].
• Surgery or Trauma: Recent wounds or surgical sites are monitored closely for complications.
• Active Lupus: If a patient has an active flare of Systemic Lupus Erythematosus (SLE), doctors may add a medication called cyclophosphamide to the treatment plan ^[7].

Life Support in the ICU

Because CAPS causes multiple organs to fail quickly, many patients require mechanical support while the medications take effect. This is not a sign that the treatment is failing, but rather a way to “buy time” for the body to heal:

• Mechanical Ventilation: A breathing machine if the lungs are affected by clots or fluid ^[8].
• Dialysis: To filter waste from the blood if the kidneys stop working ^[9].
• ECMO (Extracorporeal Membrane Oxygenation): ECMO is an uncommon, highly specialized bridge used in selected patients with otherwise refractory cardiopulmonary failure ^[10][11].

The Balancing Act: Clots vs. Bleeding

One of the most difficult challenges for your medical team is the “balancing act” between thin and thick blood. While the patient needs high doses of heparin to stop life-threatening clots, those same medications increase the risk of major bleeding ^[12]. Doctors monitor for:

• Alveolar Hemorrhage: Bleeding into the lungs ^[13].
• Intracranial Hemorrhage: Bleeding in the brain ^[14].
• Gastrointestinal Bleeding: Bleeding in the stomach or intestines ^[15].

“Rescue” Therapies

If the standard triple therapy does not stop the progression of the disease, doctors may turn to “rescue” medications. These are often used in refractory cases (cases that don’t respond to initial treatment). Their use is based mainly on case reports or small series and specialist judgment, not an established standard protocol.

• Eculizumab: A drug that blocks a part of the immune system called “complement,” which is often overactive in CAPS. It markedly increases susceptibility to meningococcal infection, requiring strict prevention measures ^[16].
• Rituximab: A medication that destroys the B-cells responsible for producing the harmful antibodies. It causes prolonged B-cell depletion and infection risks ^[17].

Survival rates have improved significantly with modern triple therapy, but recovery in the ICU is often a slow process of stabilizing one organ at a time ^[3].